ALLR实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (21 May 2024 @ 04:00):

Stats
今日成交量	4.36M
平均成交量	3.34M
市值	11.05M
EPS	$0 ( 2024-05-09 )
下一个收益日期	( $0 ) 2024-08-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.00100 (0.16%)

Insider Trading

Date	Person	Action	Amount	type
2023-08-01	Benjamin Laura	Buy	0
2023-08-01	Vazzano Joseph Walter	Buy	0
2021-12-20	Carchedi Steve	Sell	70 477	Stock Options
2021-12-20	Carchedi Steve	Sell	156 025	Stock Options
2021-12-20	Carchedi Steve	Sell	252 555	Stock Options

INSIDER POWER
0.00
Last 5 transactions
Buy: 0 \| Sell: 505 299

音量相关性

長: 0.03 (neutral)

短: 0.34 (neutral)

Signal:(55.149) Neutral

Allarity Therapeutics, 相关性

10 最正相关
JACK	0.978
APVO	0.974
LULU	0.971
EZGO	0.963
CMTL	0.961
VEEE	0.96
HAIN	0.96
SIRI	0.957
OSUR	0.957
SRNE	0.954

10 最负相关
IVCB	-0.982
BCSA	-0.966
NKTR	-0.961
PAYS	-0.958
GDST	-0.958
SWAV	-0.958
KEQU	-0.953
NSYS	-0.951
LABP	-0.951
ENTX	-0.946

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Allarity Therapeutics, 相关性 - 货币/商品

-0.75
( moderate negative )

-0.68
( moderate negative )

0.00
( neutral )

-0.53
( weak negative )

Allarity Therapeutics, 财务报表

Annual	2023
营收:	$0
毛利润:	$-37 000.00 (0.00 %)
EPS:	$-5.98

FY	2023
营收:	$0
毛利润:	$-37 000.00 (0.00 %)
EPS:	$-5.98

FY	2022
营收:	$0
毛利润:	$-120 000 (0.00 %)
EPS:	$-2 359.71

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-0.630

Financial Reports:

No articles found.

Allarity Therapeutics, Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Allarity Therapeutics,

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.